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Mutant COQ2 in Multiple-System Atrophy
To the Editor: Tsuji and colleagues (July 18 is-
sue)1 report that variants in the gene encoding 
coenzyme Q2 (COQ2) increase the risk of multi-
ple-system atrophy. They observed homozygous 
COQ2 variants encoding the substitutions M78V 
and V343A in a consanguineous Japanese family 
with multiple-system atrophy subtype P and not-
ed an association between V343A and sporadic 
multiple-system atrophy (minor-allele frequency 
[MAF], 4.8% of cases vs. 1.6% of controls; odds 
ratio, 3.05; 95% confidence interval, 1.65 to 
5.85). However, the authors erroneously labeled 
human COQ2 variability from the fourth ATG 
start codon in exon 1, which encodes the small-
est protein isoform and does not functionally 
complement the yeast coq2-null mutant.2 On the 
basis of the National Center for Biotechnology 
Information (NCBI) Reference Sequence 
(NM_015697.7), M78V should be labeled COQ2 
c.382A→G (p.M128V) and V343A should be la-
beled c.1178T→C (p.V393A). We sequenced COQ2 
in 299 Korean persons with multiple-system at-
rophy and 365 unaffected Korean persons and 
observed heterozygous COQ2 c.320G→C (encod-
ing p.S107T) and c.382A→T (encoding p.M128R) 
in 2 patients with sporadic multiple-system atro-
phy; COQ2 c.1178T→C (p.V393A) was not associ-
ated with multiple-system atrophy (MAF, 2.7% of 
cases vs. 2.6% of controls). 
It is a challenge to reconcile recessive linkage 
of homozygous COQ2 mutations in familial 
multiple-system atrophy with a heterozygous, 
presumably dominant-negative association in 
sporadic multiple-system atrophy. Respectfully, 
we suggest that Tsuji and colleagues reconsider 
whether variations in COQ2 represent a risk fac-
tor for multiple-system atrophy. Genomic multi-
plications of the SNCA 6.4-Mb locus telomeric to 
COQ2 have previously been implicated in parkin-
sonism and multiple-system atrophy3; copy 
number analysis of linked loci, or genomewide 
analysis, should be considered.
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To the Editor: Tsuji and colleagues identified 
one compound heterozygous mutation and one 
homozygous mutation in COQ2 in two multiplex 
Japanese families with multiple-system atrophy. 
The gene encodes parahydroxybenzoate-polypre-
nyl transferase, an enzyme essential to the bio-
synthesis of coenzyme Q10 (COQ10). The authors 
also described heterozygous sequence changes in 
COQ2 in sporadic cases of multiple-system atro-
phy. We directly assessed the association of these 
putative pathogenic variants with disease in a 
large European cohort of 788 persons with mul-
tiple-system atrophy, 1900 persons with Parkin-
son’s disease and 600 unaffected persons. We 
found two of the described variants in the COQ2 
gene, S347C (referred to by Tsuji and colleagues as 
S297C) and V393A (referred to by Tsuji and col-
leagues as V343A), in 1 patient each in the cohort 
of patients with Parkinson’s disease and found 
the P157S variant (referred to by Tsuji and col-
leagues as P107S) in 1 unaffected person. We did 
not observe any of the variants described by Tsuji 
and colleagues in the European cohort of pa-
tients with multiple-system atrophy, suggesting 
that these variants are population-specific.
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To the Editor: The cause of multiple-system at-
rophy is obscure. There exist reports of associa-
tion between the disease and variants in SNCA, 
the gene encoding α-synuclein, 1-3 and Tsuji and 
colleagues report an association between COQ2 
variants in Japanese patients and familial and 
sporadic clinically diagnosed multiple-system at-
rophy. Their study was based on linkage analysis 
in families with multiple-system atrophy and on 
genome sequencing, through which homozygous 
and compound heterozygous COQ2 mutants 
were detected in two families. Decreased growth 
rates in COQ2 variants identified in multiple-sys-
tem atrophy were detected in a yeast complemen-
tation assay, a finding consistent with the view 
that the association with disease was caused by 
loss of function in the protein encoded by COQ2. 
In a multicenter collaboration funded by the 
Medical Research Council of the United Kingdom, 
the Wellcome Trust, and the Multiple-System 
Atrophy Trust, we sequenced coding regions and 
flanking introns of COQ2 (ENST00000311469, 
CCDS47090.2, NM_015697.7) in more than 300 pa-
tients with neuropathologically confirmed multi-
ple-system atrophy (see the Supplementary Ap-
pendix, available with the full text of this letter 
at NEJM.org) and 262 controls, all of European 
descent.
We identified a COQ2 nonsense variant that 
was more common in controls than in persons 
with multiple-system atrophy (R22X, 24 vs. 9 al-
leles; P<0.002) and two other variants (rs6818847, 
p.V66L; and rs6535454, p.D298D), which were 
also more common in controls (see Table S1 in 
the Supplementary Appendix for provenance of 
samples). We failed to detect the variant V393A 
(referred to by Tsuji and colleagues as V343A) 
that was reported to be associated with multiple-
system atrophy in Japanese patients. (See Table 
S2 in the Supplementary Appendix for the results 
of coding of COQ2 variants.) Our data do not 
support an association between loss-of-function 
COQ2 variants and increased risk of multiple-
system atrophy in Europeans.
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To the Editor: Tsuji and colleagues describe the 
association of functionally impaired variants of 
COQ2 with parkinsonism or cerebellar ataxia in 
multiple-system atrophy, but they did not explain 
that cerebellar ataxia with variable involvement 
of the central nervous system is strongly associ-
ated with both primary and secondary COQ10 
deficiency, with onset often in adulthood.1 In 
fact, although reports suggest that COQ2 muta-
tions can cause isolated glucocorticoid-resistant 
nephropathy, to our knowledge, the first patient 
reported to harbor a homozygous COQ2 mutation 
had visual dysfunction attributed to rod–cone 
retinopathy and encephalopathy, with indications 
on magnetic resonance imaging of diffuse cere-
bral and cerebellar atrophy as well as bilateral 
lesions in the cingulate cortex and subcortical 
area.2,3 Ophthalmologic problems are also often 
observed in patients with primary COQ10 defi-
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ciencies.1 It is noteworthy, then, that the only 
proven pathogenic mutation described by Tsuji 
and colleagues (p.M78V-V343A) occurred in two 
siblings from a consanguineous family with 
multiple-system atrophy, retinitis pigmentosa, 
and low levels of COQ10 in the cerebellum, levels 
that are similar to those previously reported in 
the muscle tissue of patients with primary COQ10 
deficiency.1
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The Authors Reply: We thank Jeon and col-
leagues for bringing the matter of variant anno-
tation to our attention and have corrected the 
annotation in the article such that amino acids 
are numbered with respect to the first ATG codon 
(rather than the fourth ATG codon) in exon 1 of 
COQ2 (NCBI Reference Sequence, NM_015697.7).1 
We focused our study entirely on COQ2 variants 
occurring distal to the fourth ATG codon be-
cause the protein isoform starting at the fourth 
ATG codon has been adopted as the canonical 
sequence of the COQ2 protein in the UniProt data-
base (Q96H96 isoform-1, www.uniprot.org/uniprot/
Q96H96) and a strong cross-species conserva-
tion is observed across this isoform. In contrast, 
the cross-species conservation is weak across the 
amino-acid sequences located upstream of the 
methionine encoded by the fourth ATG codon 
(see the Supplementary Appendix, available with 
the full text of this letter at NEJM.org). Moreover, 
RNA-sequencing data available in public data-
bases, including ENCODE (http://genome.ucsc.edu/
ENCODE) and DBTSS (http://dbtss.hgc.jp), indi-
cate that the majority of the transcripts in human 
tissues start near the third or fourth ATG codon. 
Further investigations would be required to de-
termine the transcription start site and the trans-
lation initiation codon for the appropriate anno-
tation of COQ2.
Schottlaender and Houlden found that 
rs112033303 (R22X) is more common in controls 
than in cases. Because rs112033303 lies upstream 
of the fourth ATG codon, we did not include it 
in our study. We agree that their data do not 
support the association of this variant with sus-
ceptibility to multiple-system atrophy.
Jeon and colleagues, Sharma and colleagues, 
and Schottlaender and Houlden tested for asso-
ciation between COQ2 variants and multiple-sys-
tem atrophy in their case–control series and ob-
served none. Studies using larger sample sizes 
and involving tests of the effect on COQ2 func-
tion may be required to detect an association.
We reported the association of the allele fre-
quency of V393A with multiple-system atrophy 
in a Japanese series (4.8% in patients with multi-
ple-system atrophy vs. 1.6 to 2.2% in controls). 
Jeon and colleagues also found V393A in Korean 
controls, but they did not find an association 
(2.7% vs. 2.6%). In our analysis, V393A was 
strongly associated with the cerebellar subtype 
of multiple-system atrophy (6.0% vs. 1.6 to 2.2%), 
but not with the parkinsonian subtype (2.4% vs. 
1.6 to 2.2%); the statistical power to detect an 
association probably depends on the prevalence 
of each subtype in the sample tested.
Jeon and colleagues raise the possibility of 
multiplications of SNCA, located near COQ2, as a 
cause of multiple-system atrophy, but this pros-
pect seems unlikely in Family 1; our data sup-
port a recombination event between COQ2 and 
SNCA in an affected member of Family 1.
Noting that cerebellar ataxia is the most 
common clinical presentation associated with 
primary and secondary COQ10 deficiencies, 
Quinzii and colleagues suggest that the multi-
ple-system atrophy phenotype could be part of a 
broad clinical spectrum of COQ10 deficiency. It 
would also be important to investigate α-synuclein 
neuropathology in primary COQ10 deficiency.
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Albumin Replacement in Severe Sepsis or Septic Shock
To the Editor: The Albumin Italian Outcome 
Sepsis study conducted by Caironi et al. (April 10 
issue)1 is the third large-scale, randomized trial 
to compare albumin with crystalloids in adult 
patients with severe sepsis. The first such trial 
was the Saline versus Albumin Fluid Evaluation 
study.2 In addition, the Early Albumin Resuscita-
tion during Septic Shock study has been complet-
ed and its mortality results published.3
In all three trials, mortality was lower among 
patients receiving albumin, and the respective 
relative risks coincided closely, ranging from 
0.87 to 0.94 (Fig. 1). Although the effect did not 
attain statistical significance in any of the indi-
vidual trials, the pooled relative risk in all three 
trials is 0.92 (95% confidence interval [CI], 0.84 
to 1.00; P = 0.046), indicating a significant re-
duction in mortality associated with albumin 
use among adults with severe sepsis. This result 
supports the conclusion of a previous meta-
analysis involving predominantly small trials 
with different control fluids and patient popula-
tions.4 The result is also consistent with the 
observed reduction in mortality associated with 
albumin use among patients with spontaneous 
bacterial peritonitis, a disease that shares im-
portant pathophysiological features with severe 
sepsis.5
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Figure 1. Meta-Analysis of Mortality in Large-Scale Randomized Trials Comparing Albumin with Crystalloids in Adult 
Patients with Severe Sepsis. 
A fixed-effect model was used in the analysis. The size of the squares indicates the data points from the individual 
trials scaled according to the percentage of total weight (with individual trial weight equaling the proportion of total 
patients receiving albumin multiplied by the number of deaths in the crystalloids group), and the diamond indicates 
the pooled findings. The dashed line indicates the pooled relative risk. The proportion of variation attributable to 
heterogeneity (I2) was 0% (P = 0.71). ALBIOS denotes Albumin Italian Outcome Sepsis, CI confidence interval, 
EARSS Early Albumin Resuscitation during Septic Shock, and SAFE Saline versus Albumin Fluid Evaluation.
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